Effect of Choline and CDP-Choline on Inflammation and Oxidative Stress in Burkitt's Lymphoma Cells

dc.contributor.authorRoshani, Shideh
dc.contributor.authorBaris, Elif
dc.contributor.authorBosnak, Ahmet Sami
dc.contributor.authorGali-Muhtasib, Hala
dc.contributor.authorHamurtekin, Emre
dc.date.accessioned2026-02-06T18:21:36Z
dc.date.issued2025
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractBackground and Objective: Burkitt's lymphoma (BL) is a specific type of non-Hodgkin lymphoma. The BL is characterized by rapid progression and a tendency to metastasize the bone marrow and central nervous system. This study aims to evaluate the anticancer potential of choline and CDP-choline on BL cells (Ramos cells), in vitro. Materials and Methods: Ramos cells were treated with increasing concentrations of doxorubicin, choline and CDP-choline for 24 hrs after which cell viability was assessed using the MTT assay. Cytokine levels (IL-6 and TNF-) and reactive oxygen species (ROS) production were measured using ELISA and fluorometric kits, respectively. One-way Analysis of Variance (ANOVA) with post hoc Tukey-Kramer multiple comparison tests were used for the statistical analysis, p<0.05 was accepted as a statistically significant level. Results: Choline and CDP-choline treatment for 24 hrs decreased Ramos cell viability, with IC50 values of 100, 02 and 5.45 M, respectively. Both treatments increased ROS levels, indicating induction of oxidative stress. However, treatment of Ramos cells with these agents for 24 hrs did not induce cytokines (IL-6 and TNF-) production. Choline treatment increased supernatant choline levels, whereas CDP-choline had no significant effect on intracellular choline in Ramos cells. Conclusion: Choline and CDP-choline reduced cell viability of Ramos cells probably via ROS dependent mechanism, but did not induce inflammatory responses at 24 hrs post-treatment.Thesefindings suggested the possible anticancer potential ofcholine and CDP-choline against BL. This warrants further investigation into their potential therapeutic implications.
dc.identifier.doi10.3923/ijp.2025.209.216
dc.identifier.issn1811-7775
dc.identifier.issn1812-5700
dc.identifier.issue2
dc.identifier.orcid0000-0002-9195-8972
dc.identifier.orcid0000-0001-6838-7932
dc.identifier.orcid0000-0001-8305-9283
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://doi.org/10.3923/ijp.2025.209.216
dc.identifier.urihttps://hdl.handle.net/11129/9374
dc.identifier.volume21
dc.identifier.wosWOS:001455691600006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherAsian Network Scientific Information-Ansinet
dc.relation.ispartofInternational Journal of Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260204
dc.subjectBurkitt's lymphoma
dc.subjectcholine
dc.subjectCDP-choline
dc.subjectdoxorubicin
dc.subjectreactive oxygen species
dc.subjectcytotoxicity
dc.titleEffect of Choline and CDP-Choline on Inflammation and Oxidative Stress in Burkitt's Lymphoma Cells
dc.typeArticle

Files